Synlogic (SYBX) Tops Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Synlogic Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
March 17, 2022 7:00 AM EDT- Phenylketonuria (PKU) program on track for Phase 3 trial initiation in H2 2022
- Clinical readouts anticipated for PKU program in H1 2022 and in homocystinuria and enteric hyperoxaluria in H2 2022
- $136.6 million in cash, cash equivalents and marketable securities support projected runway into 2024
- Conference call and webcast at 8:30 a.m. ET today
CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology,... More
